PFE - Merck Highlights Data On New Vaccine Compares 'Tolerability And Safety' To Pfizer's | Benzinga
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent pneumococcal conjugate vaccine.
The trial evaluated the immunogenicity, tolerability, and safety of V116 compared to Pfizer Inc's (NYSE: PFE) Prevnar 20 (PCV20) in adults who had not previously received a pneumococcal vaccine.
In adults 50 years of age and older (Cohort 1), V116 elicited non-inferior ...